Immunosuppression study helps understand why some prostate cancer treatments do not work as expected

by Tampere University

New study helps understand why some prostate cancer treatments do not work as expectedOn the left is a tissue sample from the prostate stained with hematoxylin and eosin. Hematoxylin stains the nuclei blue or purple because it binds to DNA, and eosin stains the cytoplasm and proteins red or pink. This method is used in the diagnosis of prostate cancer. Visium technology (in the centre) allows for spatial genetic information to be obtained, enabling the precise study of RNA expression patterns in different areas of the tissue sample. The dots in the image are data points from which gene expression was measured. The main results of the study were obtained using this technology. On the right is a mIHC (multiplex immunohistochemistry) microscope image showing proteins stained with antibodies. This method was used for validation in the study. Credit: Antti Kiviaho, Tampere University

A recent study reveals that immunosuppression, or reduced immune response, in prostate cancer is associated with a specialized epithelial subtype.

The study, led by researchers at Tampere University, analyzed data from 120 prostate cancer patients and identified a novel interaction between the immune system and club-like epithelial cells. Although these cells share a similar origin with cancer cells, they employ a different signaling strategy and are found in areas of tissue with increased immunosuppressive activity. The findings are published in the journal Nature Communications.

Immunosuppression is a mechanism that prevents the body’s own defense system from destroying malignant cells, causing a subdued treatment response. Specifically, immunosuppression is elicited by myeloid-derived suppressor cells that infiltrate the tumor microenvironment.

“Myeloid cells are a vital component of a normally functioning immune response. In cancer, the regular function of these cells is disturbed, causing a chronic inflammation and myeloid cell accumulation in the tumor,” says Antti Kiviaho, the first author of the study.

The accumulation of myeloid cells in the tumor is associated with a poor prognosis in patients with advanced, treatment-resistant prostate cancer. Treatment resistance is a major challenge in prostate cancer management, and discovering new strategies to address this issue would lead to more effective tools for combating the disease.

Previous research has shown that blocking myeloid infiltration can re-sensitize tumors to commonly used androgen deprivation therapy, which reduces the levels of male hormones that promote tumor growth. In the study, club-like cells were found to be resistant to androgen deprivation.

“Our study implicates club-like cells in this process, but further investigation into their specific function is necessary,” adds Dr. Alfonso Urbanucci.

The study utilized technologies that allowed researchers to observe cells in their original spatial environments. This methodology was key to uncovering cell-cell interactions within the tumor microenvironment.

“Many of the previously used protocols lose the spatial information of cells, making it difficult to understand their organizational patterns in live tissue. The discovery of joint localization between club-like and myeloid cells would not have been possible without this information,” Professor Matti Nykter comments.

The study was conducted in collaboration with researchers from the Norwegian University of Science and Technology, University College London in the UK, and KU Leuven in Belgium.

More information: Antti Kiviaho et al, Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer, Nature Communications (2024). DOI: 10.1038/s41467-024-54364-1

Journal information:Nature Communications

Provided by Tampere University


Explore further

Study: Inflammatory cells in tumor microenvironment transform prostate cancer cells into treatment-resistant cells

ReplyReply to allForward

Leave a Reply

Your email address will not be published.